These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2693621)

  • 41. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B; Mouridsen HT; Jensen MB
    Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy.
    Osoba D; Erlichman C; Willan AR; Levitt M; Pater JL
    Clin Invest Med; 1986 Nov; 9(4):225-31. PubMed ID: 3542325
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiemetic activity of high-dose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients. A randomized double-blind study of the Italian Oncology Group for Clinical Research.
    Basurto C; Roila F; Tonato M; Ballatori E; Buzzi F; Calabresi F; Del Favero A
    Am J Clin Oncol; 1989 Jun; 12(3):235-8. PubMed ID: 2729180
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary nodes.
    Isacson R; Safra T; Ben-Dor CG; Uziely B; Brufman G
    Anticancer Drugs; 1993 Apr; 4(2):189-92. PubMed ID: 8490197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
    Pritchard KI; Paterson AH; Fine S; Paul NA; Zee B; Shepherd LE; Abu-Zahra H; Ragaz J; Knowling M; Levine MN; Verma S; Perrault D; Walde PL; Bramwell VH; Poljicak M; Boyd N; Warr D; Norris BD; Bowman D; Armitage GR; Weizel H; Buckman RA
    J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
    J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients.
    Roila F; Bracarda S; Basurto C; Sassi M; Lupattelli M; Picciafuoco M; Boschetti E; Del Favero A; Tonato M
    Am J Clin Oncol; 1992 Apr; 15(2):112-4. PubMed ID: 1553897
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide). A randomized, double-blind, cross-over trial.
    Diaz-Rubio E; Martin M; Rosell R; Valerdi JJ; Gonzalez-Larriba JL; Barriga JJ
    Acta Oncol; 1991; 30(3):339-42. PubMed ID: 2036244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
    Ruffert K
    Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
    Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
    J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.
    Bonneterre J; Kerbrat P; Fargeot P; Metz R; Roche H; Bastit P; Chevrier A; Tubiana-Hulin M; Geyer G; Cappelaere P
    Eur J Cancer; 1991; 27(7):849-52. PubMed ID: 1834115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer.
    Hietanen P; Teerenhovi L; Joensuu H
    Oncology; 1999; 56(2):103-9. PubMed ID: 9949294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group.
    Neoplasma; 1985; 32(3):381-7. PubMed ID: 2862594
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
    Marschner NW; Adler M; Nagel GA; Christmann D; Fenzl E; Upadhyaya B
    Eur J Cancer; 1991; 27(9):1137-40. PubMed ID: 1835624
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study].
    Pribylová O; Petruzelka L; Honová H; Fischer J; Bustová I; Siffnerová H; Kůta M; Miller V; Hacklová M; Machácek J; Kohoutek M; Vodvárka P; Kyselá T; Tajblová J; Suk J; Dorazilová V; Bauer J
    Sb Lek; 1998; 99(1):25-31. PubMed ID: 9748796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam.
    González Barón M; Chacón JI; García Girón C; Ordóñez Gallego A; García de Paredes ML; Feliu J; Zamora P; Herranz C; Garrido P; Artal A
    Acta Oncol; 1991; 30(5):623-7. PubMed ID: 1892680
    [TBL] [Abstract][Full Text] [Related]  

  • 59. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
    Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
    Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.
    Ingle JN; Foley JF; Mailliard JA; Krook JE; Hartmann LC; Jung SH; Veeder MH; Gesme DH; Hatfield AK; Goldberg RM
    Cancer; 1994 May; 73(9):2337-43. PubMed ID: 8168039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.